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ABSTRACT

!

Objective: The objective of this systematic review is to determine whether or not “Is safinamide
effective as an add-on medication in treating Parkinson's disease motor symptoms?”

!

Study design: Review of three randomized, controlled studies published in peer reviewed
journals in English between 2012-2014.

!

Data sources: The three randomized, double-blind clinical trials were found via PubMed and
EBSCOhost Web. Articles were selected based on relevance, the date of publication, and whether
or not they included patient outcomes.

!

Outcomes measured: Among other measures, each trial measured improvement in motor
symptoms using the Unified Parkinson’s Disease Rating Scale (UPDRS) Part III (motor) scores,
a clinician-scored motor evaluation.

!

Results: UPDRS III scores significantly improved in 100 mg/day safinamide experimental group
compared to the placebo control group.

!

Conclusions: All three of the randomized clinical trials included in this review indicated that
safinamide 100 mg/day is an effective add-on medication to dopaminergic drugs in improving
motor function and reducing motor fluctuations.

!
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disease resulting in diverse
clinical features that include nonmotor symptoms, motor symptoms, and classic signs like
tremor, akinesia, and rigidity.1 A single causative agent of PD is unknown. There is no direct
evidence to support genetic or environmental factors as single causative agents but it is theorized
that both are involved.2 There is evidence of six genes that have been implicated as causes of
familial PD.2
The worldwide incidence of PD is about 315 per 100,000 for people 40 years and older,
specifically 1,903 per 100,000 for the 80+ age group.3 With this data, the prevalence of PD is
projected to be 7.5 million persons worldwide with a diagnosis.3 The prevalence in men is higher
than women for all age groups.3
The population with PD acquired medical expenses of approximately $14 billion in 2010,
57% of which is associated with nursing home services.4 Estimated medical costs alone
attributed to PD were about $8 million in 2010, and another $6 million was estimated as indirect
costs to the PD population like reduced household income and lost employment.4 The population
with PD acquired approximately 1.9 million hospital inpatient days in 2010.4 Excess health-care
use attributed to PD in 2010 includes 1.26 million physician office visits, 57,000 outpatient
visits, 31,000 emergency visits, 24,000 home health days, and 26,000 hospice days.4
Pathologically PD is characterized by progressive death of dopaminergic neurons within
the substantia nigra pars compacta.1 Levodopa remains one of the most effective drugs in treating
PD because it’s converted into dopamine after crossing the blood brain barrier, however, one of
the long term effects of the drug is dyskinesia. The motor complications, such as motor
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fluctuations and dyskinesia, from levodopa are treated with other medications like monoamine
oxidase type B inhibitors, amantadine, anticholinergics, β-blockers, or dopamine agonists.5
Monoamine oxidase-B (MAO-B) inhibitors are used to treat dyskinesia due to
dopaminergic drug therapy. Safinamide is a reversible inhibitor of MAO-B and also exhibits
inhibition of stimulated release of glutamate.6 The proposed connection between glutamate
release and the development of dyskinesia supports the theory that safinamide, and its action
against glutamate, will be successful in improving motor symptoms.6 This paper evaluates three
randomized, double-blind, controlled trials comparing the efficacy of safinamide 100 mg/day at
improving motor symptoms versus a placebo group.
Objective
The objective of this systematic review is to determine whether or not safinamide is
effective as an add-on medication in treating Parkinson's disease motor symptoms.
Methods
Three double-blinded, randomized controlled trials were used in this review. The
population includes PD patients with mid to late PD or a PD diagnosis of less than 5 years in
duration. The intervention used was safinamide 100 mg/day as add-on therapy to levodopa or
other dopaminergic drugs compared to a placebo group. The outcome being measured was the
change in motor symptoms with the addition of safinamide 100 mg/day. This was measured by
clinician scoring with the UPDRS Part III score, which focuses on motor symptoms.
The key words used while searching for relevant clinical trials were safinamide,
Parkinson’s disease, randomized or RCT. All the articles were obtained through PubMed and
EBSCOhost Web, and were selected based on the date of publication and whether or not they
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included patient outcomes. All three articles were published in English in peer-reviewed journals,
two in 2014 and one in 2012. The inclusion criteria for the studies included patients with a
clinical diagnosis of PD, and randomized, controlled, double blind clinical trials. Exclusion
criteria included patients who had previous safinamide treatment, evidence of dementia or
psychiatric illness, and patients who had disabling dyskinesia or wide fluctuations. More detail is
displayed below in Table 1 for each individual study exclusion and inclusion criteria. The
statistics used and reported were numbers needed to harm (NNH), relative risk increase (RRI),
absolute risk increase (ARI), and p-values. The demographics and characteristics of the included
studies are shown below in Table 1.

!
!
!
!
!
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Table 1: Demographics and characteristics of included studies
Study

Type

Pts

Age

Inclusion criteria

Exclusion criteria

W/D Intervention

Borgohain,
2014

RCT

669

30-80
y/o

• motor fluctuations • late-stage PD
(> 1.5 hours’ off
experiencing severe,
time/day) while
disabling peak-dose or
receiving
biphasic dyskinesia, or
Levodopa and
unpredictable or widely
other dopaminergic
swinging symptom
treatments
fluctuations
• clinical diagnosis
• evidence of dementia,
of idiopathic PD >3
major psychiatric
years in duration
illnesses, and/or mental
illnesses
• Hoehn and Yahr
stage I to IV during
off
• able to accurately
maintain a diary

29

safinamide
100 mg/day
or placebo
as add-on
therapy to
Levodopa

Borgohain,
2014

RCT

669

mean
age 60
y/o

• mid-late stage PD
• experienced clinically
with motor
significant adverse
fluctuations
effects during Study 016
• completed Study
• showed clinically
016 prior to Study
significant deterioration
018
in motor symptoms
• treatment
compliant, continue
after Study 016
• discontinued from
Study 016 but had
completed
scheduled efficacy
evaluations at
weeks 12 and 24

30

safinamide
100 mg/day
or placebo
as add-on
therapy to a
single
dopamine
agonist

Stocchi,
2012

RCT

270

30-80
y/o

• clinical diagnosis
of idiopathic PD <
5 years in duration
• Hoehn and Yahr
stage I to III
• stable dose of
dopamine agonist
for at least 4 weeks
before screening

9
• diagnosis of substance
abuse
• end-of-dose wearing off,
on/off phenomena,
disabling dyskinesia, or
wide fluctuations
• previous safinamide
treatment
• diagnosis of psychosis or
depression
• hypersensitivity to
anticonvulsants or
antiparkinsonian agents
• severe postural
hypotension
• PD medications (except
for a single DA) during
the 4 wks before
screening
• concomitant use of
MAO inhibitors

safinamide
100 mg/day
or placebo
as add-on
therapy to a
single
dopamine
agonist
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Outcomes measured

All three studies measured motor symptom outcomes with the UPDRS Part III scores,
which is a measure of motor function done by a clinician.6,7,8 Motor fluctuations or dyskinesia
experienced by patients in the experimental treatment groups were compared to placebo groups
to determine whether or not they experienced statistically significant improvement in their
UPDRS part III total score.6,7,8
Results
This review of three RCTs compared patients with a PD diagnosis who were
experiencing stable motor fluctuations while receiving levodopa treatment with changes after
taking 100 mg/day of safinamide or a placebo. All three trials used safinamide 100 mg/day as an
experimental group compared to another dose of safinamide and a placebo group. This
systematic review focuses on the safinamide 100 mg/day experimental group in comparison to
the placebo control group without mention of the other experimental treatment dose of
safinamide. Dichotomous data was presented in all three RCTs to assess the safety and efficacy
of the therapy.6,7,8
In the Borgohain study there were a total of 669 patients who enrolled, 224 patients
randomized into the experimental safinamide 100 mg/day group and 222 patients randomized
into the placebo group.7 Patient return visits throughout the study were held at 52 different sites
in India, Romania, and Italy.7 Of the 224 patients in the safinamide 100 mg/day group, 195
completed the study with 4 lost to follow up and 2 reports of noncompliance.7 Treatment
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emergent adverse events (TEAEs) were experienced by 66% of patients in the safinamide 100
mg/day group, but more than 90% of reported TEAEs were considered mild or moderate.7 Some
of the common TEAEs reported by the safinamide 100 mg/day group were dyskinesia, cataract,
back pain, headache, and hypertension.7 Five deaths were reported in the safinamide 100 mg/day
group, 2 considered unrelated to the drug, 2 causes of death were unknown, and 1 death was a
result of a posttraumatic subdural hematoma 49 days after discontinuation of the study.7 This
cause of death was reported as a serious adverse event, but not considered a cause of death due to
safinamide.7 In the experimental safinamide 100 mg/day group, 18.3% experienced dyskinesia.7
The ARI was calculated to be 0.06.7 This means that patients taking safinamide 100 mg/day had
a 6% absolute increase in experiencing dyskinesia. The NNH was calculated to be 17.7 This
means that for every 17 patients being treated with safinamide 100 mg/day, one additional would
experience dyskinesia compared to control.
In another Borgohain study that was a continuation of the preliminary Borgohain study,
544 of the original 669 patients enrolled in a second continuation study that ended 78 weeks
from the start of the first.6 The randomized assignment of patients to treatment groups was
computer generated into an experimental safinamide 100 mg/day group and a placebo group.6
Return visits at the 52 sites where the study was being conducted were held every 12 weeks.6
Participants in the safinamide 100 mg/day experimental group were compliant to the study, with
0 reports of noncompliance.6 Of the 180 patients in the safinamide 100 mg/day group at the start
of the second study, 150 patients completed the study with 7 lost to follow up.6 TEAEs were
similar across the treatment groups and the placebo control group.6 The highest incidence of
newly emergent TEAEs, most common reported including worsening PD, dyskinesia, cataract,
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constipation, back pain, etc., was seen in the placebo group with 85.1% of patients affected.6 No
treatment related deaths occurred during the study.6 In the experimental safinamide 100 mg/day
group, 27.8% experienced dyskinesia.6 The ARI was calculated to be 0.06 and NNH was
calculated to be 17, the same as in the preliminary Borgohain study.6 This means that for every
17 patients being treated with safinamide 100 mg/day, one additional would experience
dyskinesia compared to control.
In the Stocchi study, 270 patients were randomized into study groups.8 The study was
conducted at 26 centers in Italy, Spain, the United Kingdom, India, Argentina, Chile, and
Colombia with return visits at weeks 2, 4, 8, 12, 18, and 24.8 Of the 90 patients in the
experimental safinamide 100 mg/day group, 81 patients completed the study with 0 reports of
noncompliance and 0 lost to follow up.8 TEAEs experienced across all study groups were mostly
mild or moderate, and <10% experienced TEAEs in each group.8 Some of the most common
included, nausea, abdominal pain, peripheral edema, dizziness, and tremor.8 Patients who
reported severe TEAEs, retinal vein occlusion and iron-deficiency anemia, in the safinamide 100
mg/day group totaled to 2.2% of the group, none of which caused death.8 In the experimental
safinamide 100 mg/day group, 2.2% experienced dyskinesia.8 The ARI was calculated to be
-0.045.8 This means that patients taking safinamide 100 mg/day had a -4.5% absolute increase in
experiencing dyskinesia. The NNH was calculated to be -22.8 This means that for every 22
patients being treated with safinamide 100 mg/day, one fewer would experience dyskinesia
compared to control.

!
!
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Table 2: Treatment effects

!

Study

p-value

CER

EER

RRI

ARI

NNH

Borgohain, 2014

0.0006

0.126

0.183

0.45

0.06

17

Borgohain, 2014

0.0002

0.217

0.278

0.28

0.06

17

Stocchi, 2012

0.0419

0.067

0.022

-0.67

-0.045

-22

Discussion
Safinamide, brand name Xadago, has been approved for treatment as an add-on to
levodopa or in combination with other medications for mid to late stage PD patients experiencing
motor fluctuations in the European Union, Iceland, Norway, and Lichtenstein.9 With a new drug
application under review, the launch of safinamide is anticipated in the United States in the
beginning months of 2016.9 A once daily preparation, safinamide 100 mg/day needs no
laboratory monitoring, can be taken with or without food without affecting absorption, and
doesn’t cause hallucinations or impulse control disorders like other PD medications.9,10
Safinamide is contraindicated for use in a patient with severe hepatic impairment as well
as contraindicated for use in combination with other MAO inhibitors due to the risk of
developing hypertensive crisis.9 It is not recommended to use safinamide with dextromethorphan
and to be used with caution with sympathomimetic medicines.9 Use of tricyclic antidepressants,
selective serotonin re-uptake inhibitors, and serotonin norepinephrine can cause severe adverse
events when used with safinamide.9 If used with caution, antidepressant medications can be
administered at the lowest effective doses with safinamide because of the selective and reversible
nature of safinamide as a MAO-B inhibitor.9 This does not apply to fluvoxamine or fluoxetine,
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which should be avoided when the patient is already taking safinamide.9 Currently, there doesn’t
seem to be any ongoing trials with safinamide.9
The RCTs on the effectiveness of safinamide in reducing motor fluctuation were limited
by the age of the patient population. The Borgohain studies included a wide range of patients
from 30-80 years old, but this didn’t include the subset of early onset PD which can affect
someone as early as 21 years old.6,7,11 Early onset PD is characterized as 21-40 years old at the
time of diagnosis, which comprises about 10% of the PD population.11 It would have been
valuable to evaluate the effectiveness of the novel drug on a patient who is more likely to have
familial PD with a diagnosis at a young age versus idiopathic PD.
Conclusions
Is safinamide effective as an add-on medication in treating Parkinson's disease motor
symptoms? The answer is yes. All three double-blinded RCTs provided statistically significant
data that displayed improvement in UPDRS part III total scores after treatment with safinamide
100 mg/day compared to placebo.6,7,8 The benefit of safinamide 100 mg/day as an add on
medication to dopaminergic therapy in treating dyskinesia in patients with PD outweighs the
mostly mild TEAEs recorded during the trials. For future study, more frequent return visits to
study sites, similar to the Stocchi study schedule, can be recommended to improve patient
compliance and dedication to the clinical trial.

!
!

REFERENCES
1. Lang AE, Lozano AM. Parkinson’s disease. N Engl J Med. 1998;339:1044-1053.

!
2.
!

Schapira AH. Etiology of Parkinson’s disease. Neurology. 2006;66(10 Suppl 4):S10-23.

3. Webster Ross G, Abott RD. Living and dying with Parkinson’s disease. Mov Disord.
2014;29(13):1571-1573. doi:10.1002/mds.25955

!

4. Kowal SL, Dall TM, Chakrabarti R, et al. The current and projected economic burden of
Parkinson’s disease in the United States. Mov Disord. 2013;28(3):311-318. doi:10.1002/mds.
25292

!

5. Connolly BS, Lang AE. Pharmacologic treatment of Parkinson disease. JAMA.
2014;311(16):1670-1683. doi:10.1001/jama.2014.3654

!

6. Borgohain R, Szasz J, Stanzione P, et al. Two-year, randomized, controlled study of
safinamide as add-on to levodopa in mid to late parkinson's disease. Mov Disord.
2014;29(10):1273-1280. doi:10.1002/mds.25961

!

7. Borgohain R, Szasz J, Stanzione P, et al. Randomized trial of safinamide add-on to levodopa
in parkinson's disease with motor fluctuations. Mov Disord. 2014;29(2):229-237. doi:
10.1002/mds.25751

!

8. Stocchi F, Borgohain R, Onofrj M, et al. A randomized, double-blind, placebo-controlled
trial of safinamide as add-on therapy in early parkinson's disease patients. Mov Disord.
2012;27(1):106-112. doi:10.1002/mds.23954

!

9. Deeks ED. Safinamide: first global approval. Drugs. 2015;75:701-711. doi:10.1007/
s40265-015-0389-7

!

10. Reichmann H. Modern treatment in Parkinson’s disease, a personal approach. J Neural
Transm. 2015;1-8. doi:10.1007/s00702-015-1441-1

!

11. Rezak M, Reese S, Sacks J. Young Parkinson’s handbook: a guide for patients and their
families. Staten Island, NY: American Parkinson Disease Association;2008.

